Prognosis | Jotup

Cancer Survivor Chronicles His Inspirational Healthy Journey After Alarming Diagnoses in New Book

Retrieved on:

Tuesday, February 20, 2024

Love, Social media, ALS, Courage, Friends, Life, Diagnosis, Human, Prognosis, Business administration, Family, Lung cancer, Interview, Cancer, Partnership

CLEVELAND, Feb. 20, 2024 /PRNewswire/ -- Husband and wife duo, Mark and Mary Kay Liston, invite readers on an uplifting journey of faith and resilience in their latest endeavor, "Diagnosed: Inspirational Stories After an Alarming Medical Diagnosis." This book, initially a personal diary recording Mark's battle with a shocking lung cancer diagnosis in 2022, details his 76-day medical journey while also sharing stories from 26 other individuals who faced diverse health challenges, from various forms of cancer to ALS.

Key Points:

Mark, a healthy non-smoker, found guidance through his faith as he faced the complexities of his unexpected lung cancer diagnosis that changed his life forever.
He began documenting his journey just for himself, mostly keeping track of doctor appointments and notes.
During this challenging time, both Mark and Mary Kay remained close to God through prayer and on day 40 of their journey, Mark beat cancer.
It was then that Mark knew he had a greater purpose in life and that was to share his journey with the world.

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments

Retrieved on:

Tuesday, February 20, 2024

Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.

Key Points:

Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.
Extensive pre-clinical study results across multiple tumor types suggest that TBL1 is a downstream target that is necessary for Wnt/beta-catenin-activated oncogenesis.
Tegavivint has demonstrated safety, clinical and pharmacodynamic activity in a Phase 1 clinical study of patients with desmoid tumors.
For more information about this Phase 1b/2a clinical trial of tegavivint in patients with advanced HCC, please visit www.ClinicalTrials.gov using the identifier NCT05797805.

Efemoral Medical Granted Breakthrough Device Designation

Retrieved on:

Wednesday, February 14, 2024

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration (FDA) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI).

Key Points:

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- Efemoral Medical , developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration (FDA) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI).
The device designed for above-the-knee (femoropopliteal) intervention is currently being tested in a first-in-human trial, EFEMORAL I, in investigative sites in New Zealand and Australia.
Encouraged by the early clinical results, Efemoral Medical is now developing an additional device for treating below-the-knee (infrapopliteal) arteries in patients with CLTI.
We are extremely gratified that the FDA has recognized the potential of the EVSS to benefit these patients by granting Breakthrough Device status to our device."

BodyKore CEO Shares Five Goal-Setting Strategies Inspired by His Recovery Journey

Retrieved on:

Wednesday, January 31, 2024

Leo Chang, co-founder and CEO of BodyKore , a leading commercial-grade fitness equipment company specializing in home gym design, is hoping to help change that.

Key Points:

Leo Chang, co-founder and CEO of BodyKore , a leading commercial-grade fitness equipment company specializing in home gym design, is hoping to help change that.
Airlifted to Mission Hospital, Chang's journey of recovery began with a daunting prognosis and a determination to return to his normal life for his family and company.
Chang's emotional resilience and immediate focus on recovery set the tone for his rehabilitation journey.
In line with these strategies, BodyKore is committed to supporting you in your journey towards better health and wellness.

Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium

Retrieved on:

Thursday, January 18, 2024

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA.

Key Points:

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA.
The poster will highlight the design of the ongoing REVERT LIVER CANCER study, a Phase 1b/2 trial evaluating safety and clinical activity of TTI-101, a novel STAT3 inhibitor, as monotherapy and in combination with standard of care in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).
TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3.
For more information about the REVERT LIVER CANCER trial, please visit ClinicalTrials.gov (NCT05440708) .

Duchenne Muscular Dystrophy Added to Minnesota's Newborn Screening Panel

Retrieved on:

Friday, January 26, 2024

Legislation, Research, Mentorship, Life, Policy, Diagnosis, PPMD, Prognosis, Genetic counseling, FDA, NBS, Duchenne muscular dystrophy, Anatomical pathology, Pharmaceutical industry

WASHINGTON, Jan. 26, 2024 /PRNewswire/ -- In a monumental stride towards improving the lives of children affected by Duchenne muscular dystrophy (Duchenne), Parent Project Muscular Dystrophy (PPMD) proudly announces that Minnesota has approved the addition of Duchenne to the state's newborn screening panel.

Key Points:

WASHINGTON, Jan. 26, 2024 /PRNewswire/ -- In a monumental stride towards improving the lives of children affected by Duchenne muscular dystrophy (Duchenne), Parent Project Muscular Dystrophy (PPMD) proudly announces that Minnesota has approved the addition of Duchenne to the state's newborn screening panel.
Once implemented, every one of the approximately 63,000 babies born in Minnesota annually will undergo newborn screening for Duchenne, ensuring not only early diagnosis but also equitable access to care.
Minnesota is now the third state, after Ohio and New York, to approve newborn screening for Duchenne.
This milestone represents a significant advancement in the broader effort to expand newborn screening for Duchenne to other states.

Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on:

Tuesday, January 23, 2024

Neutrophil, PST, Research, Overalls, Prostate cancer, Androgen receptor, University, Cancer, NCI, Prognosis, Metastasis, FACP, Transcriptome, MHC, Abstract, Diagnosis, Medicine, MYC, NK, Neoplasm, MAPK, DNA, Survival, HSD3B1, Disease, Drug development, ADT, E2F, Liver, PIM, Urachal cancer, Lung, POA, Physician, Renal cell carcinoma, PCA, B cell, Poster, RCC, Escape Room, AI, Immunotherapy, Recurrence, MBA, Prostate, Phenotype, PIM1, Gene expression, IL-6, Huntsman Cancer Institute, Patient, MD, Metadata, ASCO, WSP, C7, Society, PSA, FDA, NEPC, Vaccine

IRVING, Texas, Jan. 23, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points:

That's a major focus of the wide array of research Caris and our POA collaborators will proudly present at this year's ASCO GU."
The research is a collaboration with the Huntsman Cancer Institute at the University of Utah and other POA members.
Caris will present additional data from studies demonstrating the critical role of comprehensive molecular profiling in the treatment of genitourinary cancers.
The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Asia-Pacific Interventional Imaging Industry Research Report 2024 Featuring Canon, Shimadzu, Terumo, Trivitron Healthcare, and FUJIFILM

Retrieved on:

Friday, January 19, 2024

Software, Benchmarking, Patient, MRI, Diagnosis, Prognosis, Prevalence, Medical imaging

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- The "Asia-Pacific Interventional Imaging Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- The "Asia-Pacific Interventional Imaging Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The market encompasses a variety of techniques, consumables, systems, and software designed for chronic disease diagnosis and treatment.
The Asia-Pacific interventional imaging market is critical to the evolution of imaging systems, especially in medical diagnostics and therapy.
Workflow/Innovation Strategy: The Asia-Pacific interventional imaging market (by offering) has been segmented into detailed segments, including different types of interventional imaging systems, namely X-ray, CT scanners, MRI systems, and ultrasound imaging systems.

Hollywood's Portrayal of Cancer in Movies Fuels Misconceptions, New Study Finds

Retrieved on:

Wednesday, January 17, 2024

Death, Patient, JCO Oncology Practice, To Kill a Mockingbird, Knowledge, Suggestion, Palliative care, Hospice, Prognosis, Cancer, Lung cancer, Immunotherapy, CDC, Oncology, Caregiver, Toxicity, Public opinion, Physician, Estate (law)

NEWPORT BEACH, Calif., Jan. 17, 2024 /PRNewswire/ -- Hollywood films may provide an unrealistic view of cancer to individuals with cancer and their families, and can create misunderstandings about curability, treatment options, types of care available and cost, according to a study published today in JCO Oncology Practice. The study was led by David J. Benjamin, M.D., a medical oncologist at Hoag in Newport Beach, California.

Key Points:

"We found that the portrayals of cancer treatment, prognosis and cost of care in movies significantly diverge from reality and therefore may have an impact on how patients approach cancer care," said Dr. Benjamin.
The study found that the portrayal of type of cancer does not accurately reflect the most common cancers that are diagnosed.
Only four of the 100 movies addressed financial costs, with one focusing on the financial stresses associated with cancer treatment.
"Oncologists should be aware of how cancer is depicted in movies to anticipate and address potential discrepancies between patients' potential views and the reality of cancer care," the authors wrote.

AI Data Management Market worth $70.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Wednesday, January 17, 2024

Cloud services in AI data management offer flexibility, enabling businesses to scale resources up or down based on demand, optimizing costs.

Key Points:

Cloud services in AI data management offer flexibility, enabling businesses to scale resources up or down based on demand, optimizing costs.
AI data management in healthcare & life sciences sector involves the comprehensive handling of vast amounts of patient data, genomic information, clinical trial results, and other healthcare-related data.
AI Data Management Market Advantages:
Regular operations like data cleansing, normalisation, and classification are automated by AI in data management, increasing operational efficiency and lowering manual labour.
By upholding standard procedures for data processing, guaranteeing regulatory compliance, and enforcing data policies, AI-based data management systems improve data governance.